Niagen Bioscience (NAGE) vs Orchestra BioMed (OBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Orchestra BioMed (OBIO) has outperformed Niagen Bioscience (NAGE) over the past year, gaining 107.3% versus a loss of 62.1%. Over five years, OBIO leads with a -42.5% price change compared with -57.2% for NAGE. Orchestra BioMed is the larger company by market cap ($344.4 million vs $210.5 million), about 1.6 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAGE | OBIO |
|---|---|---|
| Share price | $2.66 | $5.73 |
| Market cap | $210.48M | $344.40M |
| 1-day change | -2.21% | +1.24% |
| YTD return | -57.23% | +36.39% |
| 1-year return | -62.12% | +107.33% |
| 5-year return | -57.23% | -42.54% |
| P/E ratio (TTM) | 14.00 | — |
| Forward P/E | 26.60 | — |
| EPS (TTM) | $0.19 | $-0.86 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $7.95 | $6.50 |
| 52-week low | $2.61 | $2.78 |
| Distance from 52-week high | -66.54% | -11.85% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +354.14% | +116.93% |
| Average volume | 585.78K | 299.24K |
| Shares outstanding | 79.13M | 60.11M |
| Employees | 117 | 86 |
| Sector | Health Care | Health Care |
| Industry | Medicinal Chemicals and Botanical Products | Medicinal Chemicals and Botanical Products |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- OBIO has outperformed NAGE by 169.4 percentage points over the past year.
About Niagen Bioscience
NAGE stock →Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products.
Health Care · Medicinal Chemicals and Botanical Products · 117 employees
About Orchestra BioMed
OBIO stock →Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States.
Health Care · Medicinal Chemicals and Botanical Products · 86 employees
NAGE vs OBIO FAQ
Which is bigger, Niagen Bioscience or Orchestra BioMed?
Orchestra BioMed (OBIO) is larger, with a market capitalization of $344.40M compared with $210.48M for Niagen Bioscience (NAGE).
Which stock has performed better over the past year, NAGE or OBIO?
OBIO returned +107.33% over the past 12 months, compared with -62.12% for NAGE (price return, excluding dividends). Past performance does not predict future results.
Are Niagen Bioscience and Orchestra BioMed in the same industry?
Yes. Both are classified in the Medicinal Chemicals and Botanical Products industry within the Health Care sector.